Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation
Active, not recruiting
- Conditions
- Malignant Hemopathy
- Registration Number
- NCT03965429
- Lead Sponsor
- Institut Paoli-Calmettes
- Brief Summary
Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.
- Detailed Description
a more in-depth analysis of the different immune cell sub-populations as well as serum markers (cytokines) would provide a better understanding of post-allograft immune reconstitution mechanisms and identify potential immunologic biomarkers predictive of GVH or relapse.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1020
Inclusion Criteria
- Allogeneic hematopoietic stem cell transplant for hematological malignancy
- Patients 18 years of age or older
- Signed consent to participation
- Membership in a social security scheme, or beneficiary of such a scheme.
Exclusion Criteria
- A person of legal age subject to a legal protection measure (major under guardianship, curatorship or court bail), or unable to express consent (language criteria included).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation. 5 years after HSC transplantation longitudinal study of the immune subpopulations of allografted patients for hematological malignancies.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institut Paoli-Calmettes
🇫🇷Marseille, Bouches-du Rhône, France
Institut Paoli-Calmettes🇫🇷Marseille, Bouches-du Rhône, France